Dr Djordje Filipovic is a multifaceted Pharmaceutical Executive with more than 20 years of experience in Research, Development, Marketing, Strategic Functions and General Management at local, regional and global levels. During his career he was overseeing the development and commercialization of some key Novartis small molecule and monoclonal antibody assets in Pharmaceuticals and Oncology and also served as Chairman of the Novartis Oncology Portfolio Management Board.
As CEO of AB2 Bio, Djordje will lead the company in the development and commercialization of Tadekinig alfa and will be responsible for successfully progressing AB2 Bio as a company.
Previously, Djordje was the Global Head of Learning for Novartis Pharmaceuticals building an integrated function across functional and personal learning for the Division. Prior to that, he served as Group General Manager of Novartis in Iran where he was directly accountable for all Novartis Divisions & Units and responsible for setting the foundation for transformational growth.
Earlier in his career at Novartis Djordje was General Manager for the Immunology, Dermatology & Hepatology on the AMAC (Asia Middle East Africa) Regional Executive Committee and the Oncology Business in Switzerland. He also led the Global Pharma Brand Maximization and Oncology Project & Portfolio Management functions.
Prior to joining the Research Division of Sandoz, a predecessor Company of Novartis, in 1992, as a laboratory head, Djordje worked in the field of Protein Engineering at the University of Illinois and Battelle Labs with the U.S. Department of Energy.
Djordje is a graduate of the Swiss Federal Institute of Technology (ETH) in Zürich, holding a Ph.D. in Biochemistry & Biophysics. He currently lectures at the European Center of Pharmaceutical Medicine (ECPM) and Medical School of the Basel University on Portfolio Management, Trends in Drug Development and Leadership. Djordje is also a member of the Advisory Board of the ECPM and an elected member of the Scientific Counsel of the Swiss Academy of Technical Sciences (SATW).
Dr. Schiffrin obtained his medical degree from La Plata University, Argentina, and was a research fellow at Harvard University where he studied mucosal immunology. He is a specialist in human pathology and inflammatory and immunological diseases. Before joining AB2 Bio he was a Medical Director for Nestlé Global Research and has been involved in the clinical development of multiple medical products treating inflammatory diseases and allergies.
